Publications by authors named "Ralph Insinga"

Claim this Profile
C
Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada.
Sylvi Nguyen, Elizabeth Wehler, Chloe Langevin, Arielle Bensimon, Natasha B Leighl, Ralph P Insinga

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer.
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael

Immunotherapy· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective.
Nan Qiao, Ralph Insinga, Thomas Burke, Gilberto Lopes

Pharmacoecon Open· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer.
Nan Qiao, Ralph Insinga, Gilberto de Lima Lopes Junior, John Cook, Martin Sénécal

Pharmacoecon Open· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of pembrolizumab + chemotherapy versus chemotherapy and pembrolizumab monotherapy in first line treatment of NSCLC in the US - updated analyses with additional trial follow-up.
Ralph P Insinga, Josephine L Feliciano, Nan Qiao, Kristel Vandormael, Ying Zhang

J Med Econ· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC.
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael

Cancers (Basel)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater".
Min Huang, Ralph P Insinga, Thomas Burke, Ying Zhang, Gilberto de Lima Lopes

Lung Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.
Herbert H Loong, Carlos K H Wong, Linda Kam Suet Leung, Praveen Dhankhar, Ralph P Insinga

Pharmacoecon Open· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA.
Min Huang, Gilberto de Lima Lopes, Ralph P Insinga, Thomas Burke, Flavia Ejzykowicz

Immunotherapy· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
Arjun Bhadhuri, Ralph Insinga, Patrik Guggisberg, Cédric Panje, Matthias Schwenkglenks

Swiss Med Wkly· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.
Ralph P Insinga, David J Vanness, Josephine L Feliciano, Kristel Vandormael, Sory Traore

Curr Med Res Opin· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.
Andrew M Frederickson, Stella Arndorfer, Ina Zhang, Maria Lorenzi, Ralph Insinga

Immunotherapy· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
Ralph P Insinga, David J Vanness, Josephine L Feliciano, Kristel Vandormael, Sory Traore

J Med Econ· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland.
Rebekah H Borse, Sumesh Kachroo, Chloe Brown, Eilish McCann, Ralph P Insinga

Rheumatol Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada.
Ralph P Insinga, Cédric Joyal, Alexandra Goyette, André Galarneau

BMC Anesthesiol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs.
Megan R Stafford, Asha Hareendran, Daisy S Ng-Mak, Ralph P Insinga, Ruifeng Xu

Health Qual Life Outcomes· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs associated with outpatient, emergency room and inpatient care for migraine in the USA.
Ralph P Insinga, Daisy S Ng-Mak, Mary E Hanson

Cephalalgia· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada.
François Coutlée, Samuel Ratnam, Agnihotram V Ramanakumar, Ralph R Insinga, James Bentley

J Med Virol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EuroQol (EQ-5D) health utility scores for patients with migraine.
Ruifeng Xu, Ralph P Insinga, Wendy Golden, X Henry Hu

Qual Life Res· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.
Ralph P Insinga, Gonzalo Perez, Cosette M Wheeler, Laura A Koutsky, Suzanne M Garland

Cancer Epidemiol Biomarkers Prev· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.
Ralph P Insinga, Gonzalo Perez, Cosette M Wheeler, Laura A Koutsky, Suzanne M Garland

Cancer Epidemiol Biomarkers Prev· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
Ronald R White, Greg Lenhart, Puneet K Singhal, Ralph P Insinga, Robbin F Itzler

Pharmacoeconomics· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population.
Henry J Henk, Ralph P Insinga, Puneet K Singhal, Theodore Darkow

J Low Genit Tract Dis· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing incidence and economic burden of genital warts with data from a US commercially insured population.
Tracey Hoy, Puneet K Singhal, Vincent J Willey, Ralph P Insinga

Curr Med Res Opin· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.
Ralph P Insinga, Erik J Dasbach, Elamin H Elbasha

BMC Infect Dis· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis